世界の常染色体優性多発性嚢胞腎用治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3879
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、97ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、常染色体優性多発性嚢胞腎用治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（痛み＆炎症治療、腎臓結石治療、尿路感染症治療、腎不全治療、その他）、用途別市場規模（病院、診療所、外来手術センター、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・常染色体優性多発性嚢胞腎用治療の市場動向
・企業の競争状況、市場シェア
・常染色体優性多発性嚢胞腎用治療の種類別市場規模と予測2016-2027（痛み＆炎症治療、腎臓結石治療、尿路感染症治療、腎不全治療、その他）
・常染色体優性多発性嚢胞腎用治療の用途別市場規模と予測2016-2027（病院、診療所、外来手術センター、その他）
・常染色体優性多発性嚢胞腎用治療の北米市場規模2016-2027（アメリカ、カナダ）
・常染色体優性多発性嚢胞腎用治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・常染色体優性多発性嚢胞腎用治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・常染色体優性多発性嚢胞腎用治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・常染色体優性多発性嚢胞腎用治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Apotex、Novartis、Hikma Group、Cardinal Health、Otsuka Pharmaceutical、Dr. Reddy's Laboratories、Lundbeck、NuCare Pharmaceuticals、Mylan）
・結論

Market Analysis and Insights: Global Autosomal Dominant Polycystic Kidney Disease Treatment Market
The global Autosomal Dominant Polycystic Kidney Disease Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Autosomal Dominant Polycystic Kidney Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Autosomal Dominant Polycystic Kidney Disease Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Autosomal Dominant Polycystic Kidney Disease Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Autosomal Dominant Polycystic Kidney Disease Treatment market.

Global Autosomal Dominant Polycystic Kidney Disease Treatment Scope and Market Size
Autosomal Dominant Polycystic Kidney Disease Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Autosomal Dominant Polycystic Kidney Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Pain & Inflammation Treatment
Kidney Stone Treatment
Urinary Tract Infection Treatment
Kidney Failure Treatment
Others

Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Apotex
Novartis
Hikma Group
Cardinal Health
Otsuka Pharmaceutical
Dr. Reddy’s Laboratories
Lundbeck
NuCare Pharmaceuticals
Mylan

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Pain & Inflammation Treatment
1.2.3 Kidney Stone Treatment
1.2.4 Urinary Tract Infection Treatment
1.2.5 Kidney Failure Treatment
1.2.6 Others
1.3 Market by Application
1.3.1 Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Perspective (2016-2027)
2.2 Autosomal Dominant Polycystic Kidney Disease Treatment Growth Trends by Regions
2.2.1 Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Autosomal Dominant Polycystic Kidney Disease Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Autosomal Dominant Polycystic Kidney Disease Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Autosomal Dominant Polycystic Kidney Disease Treatment Industry Dynamic
2.3.1 Autosomal Dominant Polycystic Kidney Disease Treatment Market Trends
2.3.2 Autosomal Dominant Polycystic Kidney Disease Treatment Market Drivers
2.3.3 Autosomal Dominant Polycystic Kidney Disease Treatment Market Challenges
2.3.4 Autosomal Dominant Polycystic Kidney Disease Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Autosomal Dominant Polycystic Kidney Disease Treatment Players by Revenue
3.1.1 Global Top Autosomal Dominant Polycystic Kidney Disease Treatment Players by Revenue (2016-2021)
3.1.2 Global Autosomal Dominant Polycystic Kidney Disease Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Autosomal Dominant Polycystic Kidney Disease Treatment Revenue
3.4 Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Concentration Ratio
3.4.1 Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Autosomal Dominant Polycystic Kidney Disease Treatment Revenue in 2020
3.5 Autosomal Dominant Polycystic Kidney Disease Treatment Key Players Head office and Area Served
3.6 Key Players Autosomal Dominant Polycystic Kidney Disease Treatment Product Solution and Service
3.7 Date of Enter into Autosomal Dominant Polycystic Kidney Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Autosomal Dominant Polycystic Kidney Disease Treatment Breakdown Data by Type
4.1 Global Autosomal Dominant Polycystic Kidney Disease Treatment Historic Market Size by Type (2016-2021)
4.2 Global Autosomal Dominant Polycystic Kidney Disease Treatment Forecasted Market Size by Type (2022-2027)

5 Autosomal Dominant Polycystic Kidney Disease Treatment Breakdown Data by Application
5.1 Global Autosomal Dominant Polycystic Kidney Disease Treatment Historic Market Size by Application (2016-2021)
5.2 Global Autosomal Dominant Polycystic Kidney Disease Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size (2016-2027)
6.2 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type
6.2.1 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021)
6.2.2 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2022-2027)
6.2.3 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2027)
6.3 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application
6.3.1 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2021)
6.3.2 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2022-2027)
6.3.3 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2027)
6.4 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country
6.4.1 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2016-2021)
6.4.2 North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size (2016-2027)
7.2 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type
7.2.1 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021)
7.2.2 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2022-2027)
7.2.3 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2027)
7.3 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application
7.3.1 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2021)
7.3.2 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2022-2027)
7.3.3 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2027)
7.4 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country
7.4.1 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2016-2021)
7.4.2 Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size (2016-2027)
8.2 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type
8.2.1 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application
8.3.1 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Region
8.4.1 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size (2016-2027)
9.2 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type
9.2.1 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2027)
9.3 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application
9.3.1 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2027)
9.4 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country
9.4.1 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size (2016-2027)
10.2 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type
10.2.1 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application
10.3.1 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country
10.4.1 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Apotex
11.1.1 Apotex Company Details
11.1.2 Apotex Business Overview
11.1.3 Apotex Autosomal Dominant Polycystic Kidney Disease Treatment Introduction
11.1.4 Apotex Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
11.1.5 Apotex Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Autosomal Dominant Polycystic Kidney Disease Treatment Introduction
11.2.4 Novartis Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Hikma Group
11.3.1 Hikma Group Company Details
11.3.2 Hikma Group Business Overview
11.3.3 Hikma Group Autosomal Dominant Polycystic Kidney Disease Treatment Introduction
11.3.4 Hikma Group Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
11.3.5 Hikma Group Recent Development
11.4 Cardinal Health
11.4.1 Cardinal Health Company Details
11.4.2 Cardinal Health Business Overview
11.4.3 Cardinal Health Autosomal Dominant Polycystic Kidney Disease Treatment Introduction
11.4.4 Cardinal Health Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
11.4.5 Cardinal Health Recent Development
11.5 Otsuka Pharmaceutical
11.5.1 Otsuka Pharmaceutical Company Details
11.5.2 Otsuka Pharmaceutical Business Overview
11.5.3 Otsuka Pharmaceutical Autosomal Dominant Polycystic Kidney Disease Treatment Introduction
11.5.4 Otsuka Pharmaceutical Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
11.5.5 Otsuka Pharmaceutical Recent Development
11.6 Dr. Reddy’s Laboratories
11.6.1 Dr. Reddy’s Laboratories Company Details
11.6.2 Dr. Reddy’s Laboratories Business Overview
11.6.3 Dr. Reddy’s Laboratories Autosomal Dominant Polycystic Kidney Disease Treatment Introduction
11.6.4 Dr. Reddy’s Laboratories Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
11.6.5 Dr. Reddy’s Laboratories Recent Development
11.7 Lundbeck
11.7.1 Lundbeck Company Details
11.7.2 Lundbeck Business Overview
11.7.3 Lundbeck Autosomal Dominant Polycystic Kidney Disease Treatment Introduction
11.7.4 Lundbeck Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
11.7.5 Lundbeck Recent Development
11.8 NuCare Pharmaceuticals
11.8.1 NuCare Pharmaceuticals Company Details
11.8.2 NuCare Pharmaceuticals Business Overview
11.8.3 NuCare Pharmaceuticals Autosomal Dominant Polycystic Kidney Disease Treatment Introduction
11.8.4 NuCare Pharmaceuticals Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
11.8.5 NuCare Pharmaceuticals Recent Development
11.9 Mylan
11.9.1 Mylan Company Details
11.9.2 Mylan Business Overview
11.9.3 Mylan Autosomal Dominant Polycystic Kidney Disease Treatment Introduction
11.9.4 Mylan Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
11.9.5 Mylan Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Pain & Inflammation Treatment
Table 3. Key Players of Kidney Stone Treatment
Table 4. Key Players of Urinary Tract Infection Treatment
Table 5. Key Players of Kidney Failure Treatment
Table 6. Key Players of Others
Table 7. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Regions (2016-2021)
Table 11. Global Autosomal Dominant Polycystic Kidney Disease Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Regions (2022-2027)
Table 13. Autosomal Dominant Polycystic Kidney Disease Treatment Market Trends
Table 14. Autosomal Dominant Polycystic Kidney Disease Treatment Market Drivers
Table 15. Autosomal Dominant Polycystic Kidney Disease Treatment Market Challenges
Table 16. Autosomal Dominant Polycystic Kidney Disease Treatment Market Restraints
Table 17. Global Autosomal Dominant Polycystic Kidney Disease Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Players (2016-2021)
Table 19. Global Top Autosomal Dominant Polycystic Kidney Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment as of 2020)
Table 20. Ranking of Global Top Autosomal Dominant Polycystic Kidney Disease Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Autosomal Dominant Polycystic Kidney Disease Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Autosomal Dominant Polycystic Kidney Disease Treatment Product Solution and Service
Table 24. Date of Enter into Autosomal Dominant Polycystic Kidney Disease Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Autosomal Dominant Polycystic Kidney Disease Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Autosomal Dominant Polycystic Kidney Disease Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Autosomal Dominant Polycystic Kidney Disease Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Autosomal Dominant Polycystic Kidney Disease Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Autosomal Dominant Polycystic Kidney Disease Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Autosomal Dominant Polycystic Kidney Disease Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Apotex Company Details
Table 65. Apotex Business Overview
Table 66. Apotex Autosomal Dominant Polycystic Kidney Disease Treatment Product
Table 67. Apotex Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021) & (US$ Million)
Table 68. Apotex Recent Development
Table 69. Novartis Company Details
Table 70. Novartis Business Overview
Table 71. Novartis Autosomal Dominant Polycystic Kidney Disease Treatment Product
Table 72. Novartis Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021) & (US$ Million)
Table 73. Novartis Recent Development
Table 74. Hikma Group Company Details
Table 75. Hikma Group Business Overview
Table 76. Hikma Group Autosomal Dominant Polycystic Kidney Disease Treatment Product
Table 77. Hikma Group Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021) & (US$ Million)
Table 78. Hikma Group Recent Development
Table 79. Cardinal Health Company Details
Table 80. Cardinal Health Business Overview
Table 81. Cardinal Health Autosomal Dominant Polycystic Kidney Disease Treatment Product
Table 82. Cardinal Health Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021) & (US$ Million)
Table 83. Cardinal Health Recent Development
Table 84. Otsuka Pharmaceutical Company Details
Table 85. Otsuka Pharmaceutical Business Overview
Table 86. Otsuka Pharmaceutical Autosomal Dominant Polycystic Kidney Disease Treatment Product
Table 87. Otsuka Pharmaceutical Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021) & (US$ Million)
Table 88. Otsuka Pharmaceutical Recent Development
Table 89. Dr. Reddy's Laboratories Company Details
Table 90. Dr. Reddy's Laboratories Business Overview
Table 91. Dr. Reddy's Laboratories Autosomal Dominant Polycystic Kidney Disease Treatment Product
Table 92. Dr. Reddy's Laboratories Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021) & (US$ Million)
Table 93. Dr. Reddy's Laboratories Recent Development
Table 94. Lundbeck Company Details
Table 95. Lundbeck Business Overview
Table 96. Lundbeck Autosomal Dominant Polycystic Kidney Disease Treatment Product
Table 97. Lundbeck Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021) & (US$ Million)
Table 98. Lundbeck Recent Development
Table 99. NuCare Pharmaceuticals Company Details
Table 100. NuCare Pharmaceuticals Business Overview
Table 101. NuCare Pharmaceuticals Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021) & (US$ Million)
Table 102. NuCare Pharmaceuticals Recent Development
Table 103. Mylan Company Details
Table 104. Mylan Business Overview
Table 105. Mylan Autosomal Dominant Polycystic Kidney Disease Treatment Product
Table 106. Mylan Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021) & (US$ Million)
Table 107. Mylan Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Type: 2020 VS 2027
Figure 2. Pain & Inflammation Treatment Features
Figure 3. Kidney Stone Treatment Features
Figure 4. Urinary Tract Infection Treatment Features
Figure 5. Kidney Failure Treatment Features
Figure 6. Others Features
Figure 7. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Ambulatory Surgical Centers Case Studies
Figure 11. Others Case Studies
Figure 12. Autosomal Dominant Polycystic Kidney Disease Treatment Report Years Considered
Figure 13. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Regions: 2020 VS 2027
Figure 16. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Regions (2022-2027)
Figure 17. Global Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Players in 2020
Figure 18. Global Top Autosomal Dominant Polycystic Kidney Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Autosomal Dominant Polycystic Kidney Disease Treatment as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Autosomal Dominant Polycystic Kidney Disease Treatment Revenue in 2020
Figure 20. Global Autosomal Dominant Polycystic Kidney Disease Treatment Revenue Market Share by Type (2016-2021)
Figure 21. Global Autosomal Dominant Polycystic Kidney Disease Treatment Revenue Market Share by Type (2022-2027)
Figure 22. North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Type (2016-2027)
Figure 24. North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Application (2016-2027)
Figure 25. North America Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Country (2016-2027)
Figure 26. United States Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Type (2016-2027)
Figure 30. Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Application (2016-2027)
Figure 31. Europe Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Country (2016-2027)
Figure 32. Germany Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Region (2016-2027)
Figure 42. China Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Type (2016-2027)
Figure 50. Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Application (2016-2027)
Figure 51. Latin America Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Country (2016-2027)
Figure 52. Mexico Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Autosomal Dominant Polycystic Kidney Disease Treatment Market Share by Country (2016-2027)
Figure 58. Turkey Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Autosomal Dominant Polycystic Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Apotex Revenue Growth Rate in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
Figure 62. Novartis Revenue Growth Rate in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
Figure 63. Hikma Group Revenue Growth Rate in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
Figure 64. Cardinal Health Revenue Growth Rate in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
Figure 65. Otsuka Pharmaceutical Revenue Growth Rate in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
Figure 66. Dr. Reddy's Laboratories Revenue Growth Rate in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
Figure 67. Lundbeck Revenue Growth Rate in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
Figure 68. NuCare Pharmaceuticals Revenue Growth Rate in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
Figure 69. Mylan Revenue Growth Rate in Autosomal Dominant Polycystic Kidney Disease Treatment Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

以下、関連資料のご紹介

世界の多発性嚢胞腎治療薬市場規模・現状・予測（2021年-2027年）

Global Polycystic Kidney Disease Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-4730 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、多発性嚢胞腎治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ANG-3070、CIM-2、CR-8、その他）、用途別市場規模（常染色体優性多発性嚢胞腎（ADPKD）、常染色体劣性多発性嚢胞腎（A...

世界の後天性嚢胞性腎疾患治療薬市場規模・現状・予測（2021年-2027年）

Global Acquired Cystic Kidney Disease Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-3750 2021年6月 105Pages
QYResearch社発行の本調査レポートでは、後天性嚢胞性腎疾患治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（抗生物質、非ステロイド性抗炎症薬、その他）、用途別市場規模（病院、診療所、研究機関、その他）、主要地域別市場規模（北米、アメリカ...

世界のAPOL1関与腎臓病市場規模・現状・予測（2021年-2027年）

Global APOL1 Mediated Kidney Disease Market Size, Status and Forecast 2021-2027
QFJ1-5595 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、APOL1関与腎臓病の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（小分子、遺伝子組み換え、核酸療法、その他）、用途別市場規模（慢性腎臓病、末期腎臓病）、主要地域別市場規模（北米、アメリカ、欧州、アジ...

世界の多嚢胞性卵巣症候群治療市場規模・現状・予測（2021年-2027年）

Global Polycystic Ovary Syndrome Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5958 2021年6月 105Pages
QYResearch社発行の本調査レポートでは、多嚢胞性卵巣症候群治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口避妊薬、インスリン増感剤、抗うつ剤、オルニチンデカルボキシラーゼ阻害剤、アロマターゼ阻害剤、利尿剤）、用途別市場規模（病院薬局...

世界の後期慢性腎臓病治療薬市場規模・現状・予測（2021年-2027年）

Global Late Stage Chronic Kidney Disease Drugs Market Size, Status and Forecast 2021-2027
QFJ1-4413 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、後期慢性腎臓病治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（カルシウム受容体刺激薬、ビタミンDステロール、カリウムバインダー、その他）、用途別市場規模（病院薬局、オンライン薬局、小売薬局）、主...

世界のICU（集中治療室）における急性腎治療市場規模・現状・予測（2021年-2027年）

Global ICU-acquired Acute Kidney Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4343 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、ICU（集中治療室）における急性腎治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（腎前部、内在性腎、腎後部）、用途別市場規模（公立病院、私立病院）、主要地域別市場規模（北米、アメリカ、欧州、アジア...

世界の急性腎障害治療市場規模・現状・予測（2021年-2027年）

Global Acute Kidney Injury Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3757 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、急性腎障害治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（前腎性急性腎障害、後腎性急性腎障害、内在性腎性急性腎障害）、用途別市場規模（病院、外来外科センター、その他）、主要地域別市場規模（北米、ア...

世界のペイロニー病治療市場規模・現状・予測（2021年-2027年）

Global Peyronie’s Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4696 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、ペイロニー病治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（治療薬、手術）、用途別市場規模（病院、ドラッグストア）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南...

世界の腎臓/腎線維化治療市場規模・現状・予測（2021年-2027年）

Global Kidney/Renal Fibrosis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4404 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、腎臓/腎線維化治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アンジオテンシンII受容体拮抗薬（ARB）、アンジオテンシン変換酵素（ACE）阻害薬、ピルフェニドン、レニン阻害薬、バソペプチダーゼ阻...

世界のフォン・ヴィレブランド病治療市場規模・現状・予測（2021年-2027年）

Global Von Willebrand Disease Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5033 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、フォン・ヴィレブランド病治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（Veyvondi、Humate-P、Alphanate、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模...

世界の多発性嚢胞腎治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Polycystic Kidney Disease Treatment Drugs Market The global Polycystic Kidney Disease Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in anal…
世界の後天性嚢胞性腎疾患治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Acquired Cystic Kidney Disease Treatment Drugs Market The global Acquired Cystic Kidney Disease Treatment Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accura…
世界のICU（集中治療室）における急性腎治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global ICU-acquired Acute Kidney Treatment Market The global ICU-acquired Acute Kidney Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and hig…
世界の急性腎障害治療市場規模・現状・予測（2021年-2027年） Acute kidney injury (AKI) is where your kidneys suddenly stop working properly. It can range from minor loss of kidney function to complete kidney failure. Market Analysis and Insights: Global Acute Kidney Injury Treatment Market The global Acute Kidney Injury Treatment market size is projected to r…
世界の腎臓/腎線維化治療市場規模・現状・予測（2021年-2027年） Kidney/Renal fibrosis, defined as an aberrant wound healing process in response to chronic injury, is characterized by the progressive and persistent accumulation of extracellular matrix components (ECM) in the kidney, ultimately leading to renal failure. Market Analysis and Insights: Global Kidney/…